Safety is the most important question when considering any new medication. And when it comes to GLP-1 receptor agonists like semaglutide, it's one of the most thoroughly studied questions in modern medicine.
Here's what the research actually shows about the safety of GLP-1 weight loss medications.
A Medication Studied on a Massive Scale
GLP-1 receptor agonists have been studied in tens of thousands of patients:
FDA Approval History
Each approval was based on comprehensive safety and efficacy data reviewed by the FDA.
What the Research Shows About Safety
### Common Side Effects (Mild and Temporary)
The most common side effects are digestive and generally mild:
These are most common during the first weeks and with each dose increase. They typically improve over time.
### Serious Side Effects (Rare)
Serious adverse events are uncommon:
### The SELECT Trial: Key Safety Data
The SELECT trial (17,604 patients, 40-month follow-up) found:
Serious adverse events occurred in 33.4% of the semaglutide group vs. 36.4% of the placebo group, meaning semaglutide patients actually had fewer serious events.
Who Should NOT Take GLP-1 Medications
Contraindications include:
Building Trust Through Transparency
At Majesta Health, we believe in being completely transparent about both the benefits and risks of GLP-1 treatment. Every patient consultation includes a thorough review of your medical history to identify any potential risks. We don't prescribe medication to everyone, and we never will.
The Bottom Line
Based on the totality of clinical evidence, GLP-1 medications have a well-established safety profile when used under proper medical supervision. The most common side effects are mild and temporary. Serious adverse events are rare.
The key to safe use: 1. Proper medical screening before starting 2. Gradual dose escalation 3. Regular monitoring by a healthcare provider 4. Open communication about any side effects
Ready to learn more? Take our free 2-minute assessment to discuss your options with a board-certified physician.
This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider. Individual results may vary. Safety data referenced from STEP and SELECT trials published in The New England Journal of Medicine.